Antiviral Drugs - Austria

Austria

The projected revenue for the Antiviral Drugs market in Austria is estimated to reach US$145.10m by 2024.
It is expected to have an annual growth rate (CAGR 2024-2029) of 1.91%, leading to a market volume of US$159.50m by 2029.
When compared globally, United States is anticipated to generate the highest revenue, amounting to US$30,640.00m in 2024.
Austria has witnessed a surge in the demand for antiviral drugs due to the increasing number of cases of viral infections in the country.

Key regions: Brazil, India, Australia, United States, United Kingdom

Market

Region

Region comparison

Currency

Analyst Opinion

The Antiviral Drugs market in Austria has been steadily growing in recent years.

Customer preferences: Customers in Austria have shown a preference for antiviral drugs that are effective in treating a wide range of viral infections. They also tend to prefer drugs that have fewer side effects and are easily accessible.

Trends in the market: The antiviral drugs market in Austria has seen an increase in demand due to the rise in viral infections such as influenza and the recent COVID-19 pandemic. This has led to an increase in research and development of antiviral drugs, resulting in a wider range of treatment options for customers. Additionally, the market has seen an increase in the use of combination therapy, where two or more antiviral drugs are used together to treat infections.

Local special circumstances: Austria has a strong healthcare system that provides universal coverage to its citizens. This has led to increased access to antiviral drugs for customers. Additionally, there has been a push towards the use of generic drugs in the country, which has led to a decrease in the cost of antiviral drugs and increased affordability for customers.

Underlying macroeconomic factors: The Austrian economy has been growing steadily in recent years, which has led to an increase in disposable income for customers. This has allowed customers to spend more on healthcare, including antiviral drugs. Additionally, the country has a high life expectancy and an aging population, which has led to an increased demand for healthcare services, including antiviral drugs.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.